Search Medical Condition
Please enter condition
Please choose location from dropdown

Ostrava - Moravska Ostrava, Czech Republic Clinical Trials

A listing of Ostrava - Moravska Ostrava, Czech Republic clinical trials actively recruiting patients volunteers.

RESULTS

Found (134) clinical trials

Mucolytic Solution Before Upper Endoscopy

Residual gastric content containing mucus, bubbles, bile and food particles may limit visibility of gastric mucosa and therefore diagnostic yield of upper endoscopy, especially in cases of early neoplastic lesions. Data on benefit of peroral mucolytic solution administered before upper endoscopy are limited.

Phase N/A

1.29 miles

Learn More »

Balloon Eustachian Tuboplasty in Treatment of Chronic Eustachian Tube Dysfunction

The prevalence of Eustachian tube (ET) dysfunction in adults reaches 1%. It causes a feeling of fullness in the ear, otalgia and hearing loss and can lead to recurrent acute otitis media, development of chronic otitis media with effusion and cholesteatoma. Endoscopic transnasal balloon ET dilatation is a novel surgical ...

Phase N/A

1.29 miles

Learn More »

Long Term Effectiveness of Dacryocystorinostomy With and Without Bicanalicular Intubation

Dacryocystorinostomy (DCR) is an operation that is indicated for lacrimal duct obstruction. Lacrimal duct obstruction can be caused by inflamation and trauma or might be the consequence of previous surgery in the lacrimal duct region. As a result of the lacrimal duct obstruction, tears are retained over the obstacle and ...

Phase N/A

1.29 miles

Learn More »

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd) Then Maintenance With Ixazomib (IXA) or IXA-Dara

INDUCTION AND CONSOLIDATION REGIMEN: Arm Dara-VCd: Daratumumab: 16 mg/Kg given by IV infusion on days 1, 8, 15, 22, on cycles 1-2 and on days 1, 15 on cycles 3-4. Bortezomib: 1.3 mg/m2 given subcutaneous (SC) injection on days 1, 8,15, 22; Cyclophosphamide: 300 mg/ m2 given orally or by ...

Phase

1.29 miles

Learn More »

Daratumumab VELCADE (Bortezomib) Lenalidomide and Dexamethasone Compared to VELCADE Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Background of the study: The combination of daratumumab with VRd is anticipated to further improve response rates in patients and may lead to improved long-term outcomes in newly diagnosed patients with multiple myeloma. Given this potential, and based upon the initial safety and efficacy observed in the ongoing Phase 2 ...

Phase

1.29 miles

Learn More »

Technical Modifications of Appendicular Stump Closure During Laparoscopic Appendectomy

Acute appendicitis presents one of the most common surgical illnesses which affect approximately 7% of the western population. In the Czech Republic, 11664 patients were hospitalized and operated for the diagnosis of acute appendicitis (K35-K38) during 2016. It might seem that the procedure of appendectomy will be guided by a ...

Phase N/A

1.29 miles

Learn More »

Treatment of In-Stent Restenosis 2 Study

Current therapy for in-stent restenosis (ISR) is based on the drug-eluting stents (DES) or drug-eluting balloon catheters (DEB). In clinical practice, paclitaxel is used as an effective antiproliferative agent loaded into DEB (paclitaxel-eluting balloon catheters; PEB). In contrast to paclitaxel, sirolimus is difficult to deliver on the balloon surface, due ...

Phase

1.29 miles

Learn More »

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (300/L). Eligible patients must have a history of 2 moderate and/or severe COPD exacerbations in the previous year ...

Phase

1.29 miles

Learn More »

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.

Phase

1.29 miles

Learn More »

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A

Primary objective: To demonstrate that tralokinumab in combination with TCS is superior to placebo in combination with topical corticosteroids (TCS) in treating severe AD in subjects who are not adequately controlled with or have contraindications to oral cyclosporine A (CSA). Secondary objectives: To evaluate the efficacy of tralokinumab in combination ...

Phase

1.29 miles

Learn More »